Company Information

Corporate History

2004
MAR.2004
Incorporated Oncolys BioPharma Inc. in Minato-ku, Tokyo for the research and development of oncolytic viruses and molecular targeted anti-cancer drugs
2005
MAY.2005
Obtained a grant from NEDO (New Energy and Industrial Technology Development Organization) for research on OBP-401 (TelomeScan®) entitled "Molecule Imaging Device Research and Development Project/Malignant Tumor Treatment Support Molecule Imaging Device Research and Development Project"
2006
MAR.2006
Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-301 (Telomelysin®)
JUN.2006
Concluded a worldwide Exclusive License Agreement with Yale University (U.S.A.) on a new HIV drug, OBP-601(Censavudine) and started research and development on it
OCT.2006
Established Kyoto Research Center in Kyoto-city, Kyoto Japan Patent 3867968 of OBP-301 (Telomelysin®) was issued.
OCT.2006
Started Phase I clinical trial in the U.S. for Telomelysin®
2007
SEP.2007
Received the Grand Prix of the 5th Japan Bio-Venture Award (sponsored by FujiSankei Business i)
NOV.2007
Moved Kyoto Research Center to Kobe-city, Kobe, and named Kobe Research Center
2008
MAR.2008
Concluded a Strategic Alliance Agreement with Medigen Biotechnology Corp. (Taiwan) for OBP-301 (Telomelysin®) Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-601(Censavudine)
MAY.2008
Started Phase Ia clinical trial in the U.S. for OBP-601(Censavudine)
AUG.2008
Filed an application to start Phase Ib/IIa clinical trial with French National Agency for the Safety of Health Products (AFSSAPS) for OBP-601(Censavudine)
2009
JAN.2009
Started Phase Ib/IIa clinical trial in France for OBP-601(Censavudine)
SEP.2009
U.S. Patent 7,589,078 of OBP-601(Censavudine) was issued.
OCT.2009
Concluded a worldwide exclusive license agreement with Astellas Pharma Inc. on a novel molecular targeting anti-cancer drug, and started research and development of OBP-801
2010
JUL.2010
Obtained a grant from NEDO for OBP-401 (TelomeScan®) as Innovation Promotion Program for fiscal 2010
DEC.2010
Concluded a worldwide Exclusive License Agreement with Bristol-Myers Squibb Co. (U.S.A) for OBP-601(Censavudine)
2011
APR.2011
Concluded an exclusive worldwide license agreement with National Institute of Biomedical Innovation for OBP-1101 (TelomeScan F35) and started research and development of OBP-1101 (TelomeScan F35)
JUN.2011
Established Oncolys Diagnostics Inc. by a method of corporate spin-off to transfer the diagnostic business including OBP-401 (TelomeScan®)
OCT.2011
Received the first milestone payment from Bristol-Myers Squibb Co. (U.S.A.)
NOV.2011
Received a 2011 Deals of Distinction Award from the Licensing Executives Society (U.S.A. and Canada) in the Industry-University-Government Interface category for out-license of OBP-601(Censavudine)
2012
MAR.2012
Started Phase IIb clinical trial of OBP-601(Censavudine) in 94 institutions in 17 countries by Bristol-Myers Squibb Co. (U.S.A.) and received the second milestone payment
APR.2012
Merged with consolidated subsidiary, Oncolys Diagnostics Inc.
Started contract testing service using OBP-401 (TelomeScan®) for research purpose U.S. Patent 8,163,892 of OBP-301 (Telomelysin®) was issued.
AUG.2012
Concluded a collaboration research agreement with Juntendo University regarding OBP-401 (TelomeScan®)
SEP.2012
Concluded a collaboration research agreement with National Hospital Organization Kure Medical Center and Chugoku Cancer Center regarding OBP-401 (TelomeScan®)
NOV.2012
Obtained a grant from JST (Japan Science and Technology Agency) as Feasibility Study (FS) Stage, Seeds Validation Type in Adaptable and Seamless Technology Transfer Program through Target-Driven R&D (A-Step) for OBP-401 (TelomeScan®)
2013
FEB.2013
Concluded a worldwide exclusive license agreement with Geron Corporation for licensing patents concerning human telomerase specific reverse transcriptase (hTERT) promoter for diagnostic use in cancer
MAY.2013
Obtained a grant from NEDO for OBP-801 as Innovation Promotion Program of Venture Support for fiscal 2010
DEC.2013
Oncolys BioPharma was listed on the Tokyo Stock Exchange Mothers.
2014
NOV.2014
Started Phase I/II clinical trial in the Korea & Taiwan for Telomelysin®
NOV.2014
Filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for OBP-801
DEC.2014
Concluded a Korean Exclusive License Agreement with WONIK CUBE Corp. (Korea) for OBP-1101(TelomeScan F35)
2015
MAY.2015
Started Phase I clinical trial in the U.S. for OBP-801
AUG.2015
Started research and development of OBP-702 & OBP-405
Nov.2015
Concluded a license agreement with Liquid Biotech USA, Inc. for TelomeScan® (OBP-401) for North America
2016
May.2016
Signed a revised license agreement with Wonik Cube Corp in Korea for OBP-1101
Jun.2016
Signed a joint research agreement with Graduate School of Medicine, Kyoto University, to investigate new compounds which activate RECK (Reversion-inducing-cysteine-rich protein with kazal motifs)
Jul.2016
Concluded a joint research agreement with Graduate School of Medicine, Nagoya University, for Telomelysin® (OBP-301) combined with checkpoint inhibitor.
Aug.2016
Concluded an investigator-initiated trial agreement with National Cancer Center Hospital East for Telomelysin® (OBP-301) combined with other therapies.
Aug.2016
Concluded a collaboration research agreement with Kyoto Prefectural University of Medicine for OBP-801 for glaucoma surgery
Aug.2016
Submitted a protocol of Telomelysin® (OBP-301) to the Food and Drug Administration (FDA), for a Phase II clinical trial in the United States, for melanoma
pagetop